News | May 23, 2012

Accumetrics Sees Significantly Increased Interest in VerifyNow P2Y12 Test as Plavix Loses Patent Protection

Platelet Reactivity Testing Can Benefit Patients, Providers and Payers

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that the introduction of multiple, new generic versions of clopidogrel into the U.S. market has led to increased interest in platelet reactivity testing. In addition to increased field interest, Accumetrics reports a 40 percent jump in traffic to its VerifyNow website.

While the less expensive, generic versions of clopidogrel provide a cost benefit to patients and insurers, it has been well-established that approximately one-third of patients do not respond adequately to clopidogrel.

"Inadequate response to clopidogrel is associated with a significantly increased rate of adverse events, such as heart attack and stent thrombosis, which can lead to 30-day rehospitalization,” said Matthew J. Price, M.D., of the Scripps Translational Science Institute and Scripps Clinic in La Jolla, Calif. “For the best overall healthcare quality and cost metrics, getting the right patient on the right drug is critical. Rapid, point-of-care platelet reactivity testing helps us determine the most appropriate antiplatelet treatment option."

Payers can also benefit from integrating platelet reactivity testing into managed care. In fact, several health plans across the nation have already created prior authorization requirements for the more potent branded drugs, Effient and Brilinta, with clopidogrel non-responsiveness as justification for prescribing them.

“Due to the increased cost of newer, more potent P2Y12 inhibitors, we often have third-party payers in this area decline payment unless it has been proven that the patient does not respond to clopidogrel,” said Paul Huang, M.D., interventional cardiologist at Seattle’s Swedish Heart and Vascular Institute. “The VerifyNow P2Y12 Test results have satisfied the payers in this area.”

John Mackowiak, Ph.D., of the Center for Outcomes Research, Nashville, Tenn., has developed a pharmacoeconomic model analyzing the budget impact of antiplatelet therapy management alternatives. “A health plan that adds platelet reactivity testing for stent patients on antiplatelet therapy could save 3-5 percent of their costs annually through reduced drug and rehospitalization expense,” said Mackowiak.

The VerifyNow System is currently used clinically by physicians in more than 800 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

"The VerifyNow System’s PRU results have become a standard tool to help healthcare professionals determine the most cost-effective and clinically appropriate solutions for patients on antiplatelet medications," said Timothy I. Still, president and CEO of Accumetrics. “Accumetrics foresees continued strong demand worldwide for our portfolio of VerifyNow platelet reactivity tests.”

For more information: www.accumetrics.com.

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init